<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5767">
  <stage>Registered</stage>
  <submitdate>6/01/2016</submitdate>
  <approvaldate>6/01/2016</approvaldate>
  <nctid>NCT02652377</nctid>
  <trial_identification>
    <studytitle>EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EDP-494-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - EDP-494
Treatment: drugs - Placebo

Experimental: EDP-494 SAD Cohorts - EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration

Experimental: EDP-494 MAD/POC Cohorts - EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days

Placebo Comparator: EDP-494 SAD Placebo Cohort - 

Placebo Comparator: EDP-494 MAD/POC Placebo Cohort - 


Treatment: drugs: EDP-494
10, 100 and 200 mg capsules

Treatment: drugs: Placebo
placebo to match EDP-494

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, and abnormal clinical laboratory results administered to healthy volunteers and multiple doses of EDP-494 - Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, echo and abnormal clinical laboratory results (including chemistry, hematology, and urine).
Administered to healthy volunteers and multiple doses of EDP-494 administered to healthy volunteers and subjects with Chronic Hepatitis C (CHC) genotype 1 and 3 infection</outcome>
      <timepoint>From screening and baseline to the 4 week follow-up visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax - EDP-494 and metabolites</outcome>
      <timepoint>0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72 (Day 4), 96 (Day 5), 120 (Day 6)*, 144 (Day 7) and 168 (Day 8) hrs postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cmax - EDP-494 and metabolites</outcome>
      <timepoint>Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose); Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC - EDP-494 and metabolites</outcome>
      <timepoint>0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120*, 144, and 168 hrs postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AUC - EDP-494 and metabolites</outcome>
      <timepoint>Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose);Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in plasma HCV RNA (log10 IU/mL)</outcome>
      <timepoint>Baseline up to 14 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amino Acid Changes in HCV polymerase NS5b</outcome>
      <timepoint>Baseline up to 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 55
             years, inclusive.

          -  Female subjects must be of non-childbearing potential.

          -  All male participants who have not had a vasectomy must use effective contraception
             from Day -1 to 90 days after their last dose of study drug.

          -  Body mass index of 18 to 30 kg/m2 with a minimum body weight of 50 kg.

          -  An informed consent document signed and dated by the subject.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

          -  Clinically relevant evidence or history of illness or disease

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at screening or Day -1.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy).

          -  History of regular alcohol consumption

          -  Participation in a clinical trial within 30 days prior to study drug administration.

          -  Use of prescription drugs, non-prescription drugs, dietary supplements, herbal
             supplements, hormonal therapy/replacement or CYP3A4 substrates, inducers and
             inhibitors within 14 days prior to the first dose of study medication

        Inclusion Criteria for HCV-Infected Subjects (POC Phase):

          -  Males and females aged 18 years and less than 70 years.

          -  Female subjects must be of non-childbearing potential.

          -  All male participants who have not had a vasectomy must use effective contraception
             from Day -1 to 90 days after their last dose of study drug.

          -  Body mass index of 18 to 36 kg/m2 with a minimum body weight of 50 kg.

          -  Treatment na√Øve subjects with chronic HCV infection,

          -  HCV GT1 (including 1a, 1b, or mixed subtypes of GT1) or GT3.

          -  HCV RNA =100,000 IU/mL at screening.

          -  An informed consent document signed and dated by the subject.

        Exclusion Criteria for HCV-Infected Subjects (POC Phase):

          -  Women of childbearing potential (WOCBP).

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug.

          -  A positive urine drug screen at screening unless on an approved prescription.

          -  History of participation in a clinical trial with a polymerase inhibitor or previous
             treatment with a polymerase inhibitor, where at least one dose of the polymerase
             inhibitor was consumed. Subjects who were dosed with placebo on a clinical trial may
             be enrolled in this study.

          -  Clinically significant electrocardiogram abnormalities or QTcF greater than 450 msec
             for males and 470 msec for females at either screening or baseline, or any prior
             history of QT abnormality.

          -  Co-infection with HIV-1, HIV-2 or HBV.

          -  Have clinically significant laboratory abnormalities at screening:

               -  Absolute neutrophil count (ANC) &lt; 1500/mm2 (1.5 x 109L)

               -  Platelets &lt;90,000/mm2 (90 x 109L)

               -  Hemoglobin &lt; 13g/dL for males and &lt; 12g/dL for females

               -  Serum creatinine &gt;1.5 x upper limit of normal (ULN) or creatinine clearance &lt; 50
                  mL/min; estimated by the cockcroft -Gault formula [(140-age) x weight (kg)/72 x
                  serum creatinine (mg/dL), if female multiply by 0.85]

               -  Total bilirubin greater than the ULN

               -  Serum alanine transaminase (ALT) &gt; 5 x ULN

               -  Serum aspartate aminotransferase (AST) &gt; 5 x ULN

               -  Alkaline phosphatase &gt; 1.25 x ULN

               -  Pancreatic Amylase &gt; 1.1 x ULN

               -  Alpha fetoprotein (AFP) &gt; 50 ng/mL unless a liver imaging study (CT, MRI) shows
                  no clinically significant lesions within 6 months prior to the first dose of
                  study drug.

          -  Patients with evidence of cirrhosis; cirrhosis is defined as any one of the following:
             a) any biopsy showing cirrhosis (Knodell score &lt;3, Metavir score &lt;3, Ishak score &lt;4);
             b) Fibroscan evaluation within 6 months prior to screening with a liver stiffness
             score of &gt;&lt;12.5 kPa.

          -  Other significant, unstable or uncontrolled medical history, such as neurological,
             endocrine, malignancy, renal, psychiatric, respiratory, cardiac, gastrointestinal,
             allergic, immunological, etc. disease.

          -  Use of concomitant medications, including vitamins or herbal and dietary supplements
             within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study
             medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>10/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>27/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Enanta Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novotech (Australia) Pty Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of
      a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV)
      and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02652377</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edward Gane, MD</name>
      <address>Auckland Clinical Studies (ACS),</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>